Amgen’s Lumykras (sotorasib) Receives NICE Recommendation for the Treatment of Non-Small-Cell Lung Cancer
Shots:
- The NICE has issued a FAD recommending the use of Amgen’s Lumykras (sotorasib) on the NHS as a therapy option for the treatment of KRAS G12C mutation+ LA or metastatic NSCLC who have progressed or are intolerant to Pt-based CT & immunotherapy
- The CMA was based on the P-II (CodeBreaK 100) trial to evaluate sotorasib in 126 patients with KRAS G12C- mutated advanced NSCLC. The results showed an ORR (37.1%) & OS (12.5mos.), m-DoR (10mos.) in 46 patients with ORR
- The therapy will be available to patients in England via the Cancer Drugs Fund. Lumykras is an oral targeted therapy & has received a CMA from the MHRA for use across England, Scotland and Wales under Project Orbis
Ref: NICE | Image: Adweek
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
